Quick context
ADAMAX
该名称缺乏科学及监管标准化；不同供应商所指成分和宣称可能不同。
The name does not identify a reliably standardised substance. Dose, reconstitution and risk calculations are not dependable without confirmed identity and composition.
Back to all 64 profiles
Identity insufficiently defined身份不明确
Community protocol · ADAMAX
ADAMAX: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: Adamax peptide · vendor shorthand
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Identity insufficiently defined
The name does not identify a reliably standardised substance. Dose, reconstitution and risk calculations are not dependable without confirmed identity and composition.
Amount status
There is no dependable amount without confirmed identity.
Profile evidence level: unclear.
Timing
Timing claims are meaningless when identity is unresolved.
No individual recommendation.
Cycle/duration
A cycle cannot be described responsibly for an undefined substance.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
No generic calculator
No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.
No responsible U-100 conversion can be made for blends or vaguely named products until each component amount, total volume and verified composition are unambiguous.
Mechanism and research questions
Non-standardised name used in online peptide catalogues
ADAMAX is classified as “Non-standardised name used in online peptide catalogues”. 该名称缺乏科学及监管标准化；不同供应商所指成分和宣称可能不同。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
目录命名不明确
这涉及商家名称并不对应某种单一、科学定义的物质,类似于一个可能指代不同事物的绰号。研究人员和分析人员会核查该名称背后实际的成分构成。
未识别物质名称
这说明该名称无法与任何已知的、经科学描述的物质对应,类似于没有可识别内容的标签。缺乏鉴定,就无法就其效应或安全性提出有意义的研究问题。
产品身份检测
这涉及用于确定产品实际成分的实验室分析,类似于核对成分标签与包装内实际物品是否相符。研究人员或分析人员通常使用化学检测方法来鉴定和量化实际内容物。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
目录命名混淆
用户试图厘清模糊的商家名称或代码标签背后实际是什么物质,通常通过比较标签和商家说法进行。这类论坛猜测并不是可靠的物质鉴定方式。
商家营销宣传
商家常常以宽泛的功效宣称、与竞品的对比表格以及客户评价来推广产品。这类营销言论受销售利益驱动,并不构成独立的科学疗效证据。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 中枢神经系统影响可能包括疲劳、躁动、头痛、眩晕、睡眠或情绪变化。未获批物质的相互作用及长期神经精神安全性不明确。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠、癫痫、严重精神或神经系统疾病，以及合并镇静或兴奋药物，均需医学评估。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 研究可根据终点评估认知、睡眠、情绪、生命体征及不良事件；每日主观感受不能替代标准化测量。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
尚不明确
由于成分和供应商声称各不相同,无法可靠评估其证据情况。
Published evidence
该产品的实际成分或身份无法可靠确认,因此无法恰当评估其证据情况。
ADAMAX并非经科学标准化的名称,这使其有别于具名且定义明确的研究肽。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
身份不明确
名称或配方缺乏足够标准化，无法可靠判断监管分类。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: official drug-label search
- Primary/technical sourcePubMed: biomedical literature database
- Community referenceADAMAX — Peptide Dosing Protocols